Biophysical characterization and immunization studies of dominant negative inhibitor (DNI), a candidate anthrax toxin subunit vaccine

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 11, 2013, Pages 2362-2370

  Iyer, Vidyashankara ^a,b   Hu, Lei ^a   Schanté, Carole E ^a   Vance, David ^c   Chadwick, Chrystal ^c   Jain, Nishant Kumar ^a   Brey, Robert N ^d   Joshi, Sangeeta B ^a   Volkin, David B ^a,b   Andra, Kiran K ^e   Bann, James G ^e   Mantis, Nicholas J ^c   Middaugh, C Russell ^a,b  

^a UNIVERSITY OF KANSAS   (United States)

^b University of Kansas   (United States)

^c WADSWORTH CENTER   (United States)

^d Soligenix Inc   (United States)

^e WICHITA STATE UNIVERSITY   (United States)

Author keywords

Accelerated stability; Aluminum hydroxide; Biophysical characterization; Dominant negative inhibitor; Immunogenicity; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; ANTHRAX VACCINE; DOMINANT NEGATIVE INHIBITOR PROTEIN; NEUTRALIZING ANTIBODY; RECOMBINANT ANTIGEN; UNCLASSIFIED DRUG; ANTHRAX TOXIN; BACTERIAL ANTIGEN; BACTERIAL TOXIN; IMMUNOLOGICAL ADJUVANT; PROTEIN SUBUNIT; SUBUNIT VACCINE;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; BIOPHYSICS; CONTROLLED STUDY; DRUG MEGADOSE; DRUG STABILITY; FREEZE DRYING; IMMUNOGENICITY; LOW DRUG DOSE; MOUSE; NONHUMAN; STORAGE TEMPERATURE; TEMPERATURE STRESS; THERMOSTABILITY; ANIMAL; ANTHRAX; BACILLUS ANTHRACIS; BAGG ALBINO MOUSE; CHEMISTRY; IMMUNIZATION; IMMUNOLOGY; PROCEDURES; PROTEIN CONFORMATION; PROTEIN STABILITY; PROTEIN SUBUNIT; RADIATION RESPONSE; TEMPERATURE;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; BIOPHYSICAL PHENOMENA; DRUG STABILITY; FREEZE DRYING; IMMUNIZATION; MICE, INBRED BALB C; PROTEIN CONFORMATION; PROTEIN STABILITY; PROTEIN SUBUNITS; TEMPERATURE; VACCINES, SUBUNIT;

EID: 84887452362     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.25852     Document Type: Article

References (23)

1. Dixon TC, Meselson M, Guillemin J, Hanna PC. Anthrax. N Engl J Med 1999; 341: 815-26; PMID: 10477781; http://dx.doi.org/10.1056/NEJM199909093411107 (Pubitemid 29420478)
2. Donegan S, Bellamy R, Gamble CL. Vaccines for preventing anthrax. Cochrane Database Syst Rev 2009; CD006403; PMID: 19370633
3. Inglesby T V, O ' To o l e T, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, et al.; Working Group on Civilian Biodefense. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 2002; 287: 2236-52; PMID: 1198 0524; http://dx.doi.org/10.1001/jama.287.17.2236 (Pubitemid 34441940)
4. Peachman KK, Li Q, Matyas GR, Shivachandra SB, Lovchik J, Lyons RC, et al. Anthrax vaccine antigen-adjuvant formulations completely protect New Zealand white rabbits against challenge with Bacillus anthracis Ames strain spores. Clin Vaccine Immunol 2012; 19: 11-6; PMID: 22089245; http://dx.doi.org/10.1128/ CV I.05376-11
5. Wright JG, Quinn CP, Shadomy S, Messonnier N; Centers for Disease Control and Prevention (CDC). Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2010; 59(RR-6): 1-30; PMID: 20651644
6. Castelán-Vega J, Corvette L, Sirota L, Arciniega J. Reduction of immunogenicity of anthrax vaccines subjected to thermal stress, as measured by a toxin neutralization assay. Clin Vaccine Immunol 2011; 18: 349-51; PMID: 21147935; http://dx.doi.org/10.1128/CVI.00267-10
7. Sellman BR, Mourez M, Collier RJ. Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax. Science 2001; 292: 695-7; PMID: 11326 092; http://dx.doi.org/10.1126/science.109563 (Pubitemid 32385534)
8. Yan M, Collier RJ. Characterization of dominant-negative forms of anthrax protective antigen. Mol Med 2003; 9: 46-51; PMID: 12765339 (Pubitemid 36667691)
9. Aulinger BA, Roehrl MH, Mekalanos JJ, Collier RJ, Wang JY. Combining anthrax vaccine and therapy: a dominant-negative inhibitor of anthrax toxin is also a potent and safe immunogen for vaccines. Infect Immun 2005; 73: 3408-14; PMID: 15 9 0 8 3 6 8; http://dx.doi.org/10.1128/IAI.73.6.3408-3414.2005 (Pubitemid 40745883)
10. Sellman BR, Nassi S, Collier RJ. Point mutations in anthrax protective antigen that block translocation. J Biol Chem 2001; 276: 8371-6; PMID: 1111312 6; http://dx.doi.org/10.1074/jbc.M008309200
11. Hu L, Olsen C, Maddux N, Joshi SB, Volk in DB, Middaugh CR. Investigation of protein conformational stability employing a multimodal spectrometer. Anal Chem 2011; 83: 9399-405; PMID: 22047496; http://dx.doi.org/10.1021/a c 2 019 95 c
12. Hu L, Joshi SB, Andra KK, Thakkar SV, Volk in DB, Bann JG, et al. Comparison of the structural stability and dynamic properties of recombinant anthrax protective antigen and its 2-fluorohistidine-labeled analogue. J Pharm Sci 2012; 101: 4118-28; PMID: 22911632; http://dx.doi.org/10.1002/jps.23294
13. Rajapaksha M, Eichler JF, Hajduch J, Anderson DE, Kirk KL, Bann JG. Monitoring anthrax toxin receptor dissociation from the protective antigen by NMR. Protein Sci 2009; 18: 17-23; PMID: 19177347
14. Wimalasena DS, Cramer JC, Janowiak BE, Juris SJ, Melnyk RA, Anderson DE, et al. Effect of 2-fluorohistidine labeling of the anthrax protective antigen on stability, pore formation, and translocation. Biochemistry 2007; 46: 14928-36; PMID: 18044973; http://dx.doi.org/10.1021/bi701763z (Pubitemid 350308884)
15. Kelly-Cirino CD, Mantis NJ. Neutralizing monoclonal antibodies directed against defined linear epitopes on domain 4 of anthrax protective antigen. Infect Immun 2009; 77: 4859-67; PMID: 19703971; ht tp://dx.doi.org/10.1128/I A I.00117-09
16. Jiang G, Joshi SB, Peek LJ, Brandau DT, Huang J, Ferriter MS, et al. Anthrax vaccine powder formulations for nasal mucosal delivery. J Pharm Sci 2006; 95: 80-96; PMID: 16 3152 3 0; http://dx.doi.org/10.1002/jps.20484
17. Wigelsworth DJ, Krantz BA, Christensen KA, Lacy DB, Juris SJ, Collier RJ. Binding stoichiometry and kinetics of the interaction of a human anthrax toxin receptor, CMG2, with protective antigen. J Biol Chem 2004; 279: 23349-56; PMID: 15044490; http://dx.doi.org/10.1074/jbc.M401292200 (Pubitemid 38685644)
18. Rainey GJ, Wigelsworth DJ, Ryan PL, Scobie HM, Collier RJ, You ng JA. Receptor-specific requirements for anthrax toxin delivery into cells. Proc Natl Acad Sci U S A 2005; 102: 13278-83; PMID: 16141341; http://dx.doi.org/10.1073/ pnas.0505865102 (Pubitemid 41325014)
19. Santelli E, Bankston LA, Leppla SH, Liddington RC. Crystal structure of a complex between anthrax toxin and its host cell receptor. Nature 2004; 430: 905-8; PMID: 15243628; http://dx.doi.org/10.1038/nature02763 (Pubitemid 39119219)
20. Powell BS, Enama JT, Ribot WJ, Webster W, Little S, Hoover T, et al. Multiple asparagine deamidation of Bacillus anthracis protective antigen causes charge isoforms whose complexity correlates with reduced biological activity. Proteins. Structure, Function, and Bioinformatics 2007; 68: 458-79; http://dx.doi.org/10.1002/prot.21432 (Pubitemid 46981940)
21. Verma A, McNichol B, Domínguez-Castillo RI, Amador-Molina JC, Arciniega JL, Reiter K, et al. Use of site-directed mutagenesis to model the effects of spontaneous deamidation on the immunogenicity of Bacillus anthracis protective antigen. Infect Immun 2013; 81: 278-84; PMID: 23115046; http://dx.doi.org/10.1128/IAI.00863-12
22. D'Souza AJM, Mar KD, Huang J, Majumdar S, Ford BM, Dyas B, et al. Rapid deamidation of recombinant protective antigen when adsorbed on aluminum hydroxide gel correlates with reduced potency of vaccine. J Pharm Sci 2013; 102: 454-61; PMID: 23242822; http://dx.doi.org/10.1002/jps.23422
23. Berthold I, Pombo M-L, Wagner L, Arciniega JL. Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants. Vaccine 2005; 23: 1993-9; PMID: 15734073; http://dx.doi.org/10.1016/j. vaccine.2004.10.014 (Pubitemid 40289072)